

Anna L Zignego

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6488016/publications.pdf>

Version: 2024-02-01

187
papers

9,293
citations

34100

52
h-index

45310

90
g-index

189
all docs

189
docs citations

189
times ranked

5459
citing authors

#	ARTICLE	IF	CITATIONS
1	Hepatitis C virus infection in patients with non-Hodgkin's lymphoma. <i>British Journal of Haematology</i> , 1994, 88, 392-394.	2.5	455
2	Mixed cryoglobulinemia: demographic, clinical, and serologic features and survival in 231 patients. <i>Seminars in Arthritis and Rheumatism</i> , 2004, 33, 355-374.	3.4	449
3	Infection of peripheral mononuclear blood cells by hepatitis C virus. <i>Journal of Hepatology</i> , 1992, 15, 382-386.	3.7	418
4	A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. <i>Arthritis and Rheumatism</i> , 2012, 64, 843-853.	6.7	337
5	Cryoglobulins. <i>Journal of Clinical Pathology</i> , 2002, 55, 4-13.	2.0	274
6	Extrahepatic manifestations of Hepatitis C Virus infection: A general overview and guidelines for a clinical approach. <i>Digestive and Liver Disease</i> , 2007, 39, 2-17.	0.9	222
7	Extrahepatic manifestations of chronic hepatitis C virus infection. <i>Digestive and Liver Disease</i> , 2014, 46, S165-S173.	0.9	218
8	Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients. <i>Autoimmunity Reviews</i> , 2011, 10, 444-454.	5.8	186
9	Prevalence of <i>bcl-2</i> Rearrangement in Patients with Hepatitis C Virus-Related Mixed Cryoglobulinemia with or without B-Cell Lymphomas. <i>Annals of Internal Medicine</i> , 2002, 137, 571.	3.9	185
10	Prospective study of guideline-tailored therapy with direct-acting antivirals for hepatitis C virus-associated mixed cryoglobulinemia. <i>Hepatology</i> , 2016, 64, 1473-1482.	7.3	167
11	Treatment with rituximab in patients with mixed cryoglobulinemia syndrome: Results of multicenter cohort study and review of the literature. <i>Autoimmunity Reviews</i> , 2011, 11, 48-55.	5.8	158
12	T(14;18) translocation in chronic hepatitis C virus infection. <i>Hepatology</i> , 2000, 31, 474-479.	7.3	157
13	Hepatitis C Virus Genotype Analysis in Patients with Type II Mixed Cryoglobulinemia. <i>Annals of Internal Medicine</i> , 1996, 124, 31.	3.9	153
14	Cryoglobulinaemia. <i>Nature Reviews Disease Primers</i> , 2018, 4, 11.	30.5	143
15	Extrahepatic manifestations of HCV infection: facts and controversies. <i>Journal of Hepatology</i> , 1999, 31, 369-376.	3.7	140
16	Hepatitis C virus RNA localization in human carotid plaques. <i>Journal of Clinical Virology</i> , 2010, 47, 72-75.	3.1	127
17	Preliminary classification criteria for the cryoglobulinaemic vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1183-1190.	0.9	121
18	HCV syndrome: A constellation of organ- and non-organ specific autoimmune disorders, B-cell non-Hodgkin's lymphoma, and cancer. <i>World Journal of Hepatology</i> , 2015, 7, 327.	2.0	118

#	ARTICLE	IF	CITATIONS
19	Safety and efficacy of rituximab in patients with hepatitis C virus-related mixed cryoglobulinemia and severe liver disease. <i>Blood</i> , 2010, 116, 335-342.	1.4	112
20	Hepatitis C virus-related lymphoproliferative disorders: An overview. <i>World Journal of Gastroenterology</i> , 2007, 13, 2467.	3.3	109
21	Long-term effect of HCV eradication in patients with mixed cryoglobulinemia: A prospective, controlled, open-label, cohort study. <i>Hepatology</i> , 2015, 61, 1145-1153.	7.3	107
22	Prevalence of Monoclonal Gammopathies in Patients with Hepatitis C Virus Infection. <i>Annals of Internal Medicine</i> , 1998, 129, 294.	3.9	105
23	Hepatitis C virus infection in mixed cryoglobulinemia and B-cell non-Hodgkin's lymphoma: evidence for a pathogenetic role. <i>Archives of Virology</i> , 1997, 142, 545-555.	2.1	100
24	Effect of antiviral treatment in patients with chronic HCV infection and t(14;18) translocation. <i>Blood</i> , 2003, 102, 1196-1201.	1.4	99
25	HCV-related autoimmune and neoplastic disorders: the HCV syndrome. <i>Digestive and Liver Disease</i> , 2007, 39, S13-S21.	0.9	92
26	Hepatitis C virus persistence in human hematopoietic cells injected into SCID mice. <i>Hepatology</i> , 1998, 28, 211-218.	7.3	91
27	Mixed cryoglobulinaemia: a cross-road between autoimmune and lymphoproliferative disorders. <i>Lupus</i> , 1998, 7, 275-279.	1.6	90
28	Can type C hepatitis infection be complicated by malignant lymphoma?. <i>Lancet, The</i> , 1995, 346, 1426-1427.	13.7	89
29	International diagnostic guidelines for patients with HCV-related extrahepatic manifestations. A multidisciplinary expert statement. <i>Autoimmunity Reviews</i> , 2016, 15, 1145-1160.	5.8	87
30	International therapeutic guidelines for patients with HCV-related extrahepatic disorders. A multidisciplinary expert statement. <i>Autoimmunity Reviews</i> , 2017, 16, 523-541.	5.8	87
31	Hepatitis C virus infection in non-Hodgkin's B-cell lymphoma complicating mixed cryoglobulinaemia. <i>European Journal of Clinical Investigation</i> , 1994, 24, 781-784.	3.4	85
32	Hepatitis C virus infection of mononuclear cells from peripheral blood and liver infiltrates in chronically infected patients. <i>Journal of Medical Virology</i> , 1995, 47, 58-64.	5.0	84
33	HCV and Lymphoproliferation. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-8.	3.3	84
34	Impaired immunogenicity to COVID-19 vaccines in autoimmune systemic diseases. High prevalence of non-response in different patients' subgroups. <i>Journal of Autoimmunity</i> , 2021, 125, 102744.	6.5	83
35	Hepatitis C virus-related autoimmunity in patients with porphyria cutanea tarda. <i>European Journal of Clinical Investigation</i> , 1993, 23, 851-855.	3.4	80
36	Hepatitis C virus (HCV) infection: A systemic disease. <i>Molecular Aspects of Medicine</i> , 2008, 29, 85-95.	6.4	80

#	ARTICLE	IF	CITATIONS
37	Hepatitis C virus lymphotropism: lessons from a decade of studies. <i>Digestive and Liver Disease</i> , 2007, 39, S38-S45.	0.9	75
38	Extrahepatic Manifestations of Hepatitis C Virus Infection. <i>Clinics in Liver Disease</i> , 2008, 12, 611-636.	2.1	75
39	Relation between infection and autoimmunity in mixed cryoglobulinemia. <i>Current Opinion in Rheumatology</i> , 2000, 12, 53-60.	4.3	73
40	Virus-driven autoimmunity and lymphoproliferation: the example of HCV infection. <i>Expert Review of Clinical Immunology</i> , 2015, 11, 15-31.	3.0	73
41	Evidence-based recommendations on the management of extrahepatic manifestations of chronic hepatitis C virus infection. <i>Journal of Hepatology</i> , 2017, 66, 1282-1299.	3.7	73
42	Interstitial lung fibrosis and rheumatic disorders in patients with hepatitis C virus infection. <i>British Journal of Rheumatology</i> , 1997, 36, 360-365.	2.3	72
43	Validation of the classification criteria for cryoglobulinaemic vasculitis. <i>Rheumatology</i> , 2014, 53, 2209-2213.	1.9	67
44	Infection of peripheral blood mononuclear cells by hepatitis C virus in mixed cryoglobulinemia. <i>Blood</i> , 1993, 82, 3701-4.	1.4	67
45	Low serum tryptophan levels, reduced macrophage IDO activity and high frequency of psychopathology in HCV patients. <i>Journal of Viral Hepatitis</i> , 2006, 13, 402-408.	2.0	64
46	A phase II, single-arm multicenter study of low-dose rituximab for refractory mixed cryoglobulinemia secondary to hepatitis C virus infection. <i>Autoimmunity Reviews</i> , 2011, 10, 714-719.	5.8	64
47	Relevance of inapparent coinfection by hepatitis B virus in alpha interferon-treated patients with hepatitis C virus chronic hepatitis. <i>Journal of Medical Virology</i> , 1997, 51, 313-318.	5.0	63
48	HCV infection facilitates asymptomatic carotid atherosclerosis: preliminary report of HCV RNA localization in human carotid plaques. <i>Digestive and Liver Disease</i> , 2007, 39, S55-S60.	0.9	63
49	B-cells and mixed cryoglobulinemia. <i>Autoimmunity Reviews</i> , 2007, 7, 114-120.	5.8	61
50	Genetic determinants in hepatitis C virus-associated mixed cryoglobulinemia: Role of polymorphic variants of BAFF promoter and Fcγ3 receptors. <i>Arthritis and Rheumatism</i> , 2011, 63, 1446-1451.	6.7	59
51	Cryoglobulinemia Membranoproliferative Glomerulonephritis Associated with Hepatitis C Virus. <i>American Journal of Nephrology</i> , 1993, 13, 300-304.	3.1	58
52	Triple antiviral therapy in hepatitis C virus infection with or without mixed cryoglobulinaemia: A prospective, controlled pilot study. <i>Digestive and Liver Disease</i> , 2014, 46, 833-837.	0.9	57
53	Genome-wide association study of hepatitis C virus- and cryoglobulin-related vasculitis. <i>Genes and Immunity</i> , 2014, 15, 500-505.	4.1	55
54	Erectile Dysfunction and Hepatitis C Virus Infection. <i>JAMA - Journal of the American Medical Association</i> , 2002, 288, 698-699.	7.4	55

#	ARTICLE	IF	CITATIONS
55	Genetic Diversity of the KIR/HLA System and Susceptibility to Hepatitis C Virus-Related Diseases. <i>PLoS ONE</i> , 2015, 10, e0117420.	2.5	54
56	Mixed cryoglobulinemia as a possible preneoplastic disorder. <i>Arthritis and Rheumatism</i> , 1995, 38, 1859-1860.	6.7	53
57	Efficacy of low-dose rituximab for the treatment of mixed cryoglobulinemia vasculitis: Phase II clinical trial and systematic review. <i>Autoimmunity Reviews</i> , 2015, 14, 889-896.	5.8	53
58	Hepatitis B virus related cryoglobulinemic vasculitis: A multicentre open label study from the Gruppo Italiano di Studio delle Crioglobulinemie â€“ GISC. <i>Digestive and Liver Disease</i> , 2016, 48, 780-784.	0.9	50
59	Hepatitis C virus chronic infection as a common cause of mixed cryoglobulinaemia and autoimmune liver disease. <i>Journal of Internal Medicine</i> , 1994, 236, 31-36.	6.0	47
60	Prevalence of mixed infection by different hepatitis C virus genotypes in patients with hepatitis C virusâ€“related chronic liver disease. <i>Translational Research</i> , 1999, 134, 68-73.	2.3	47
61	Longitudinal assessment of liver stiffness in patients undergoing antiviral treatment for hepatitis C. <i>Digestive and Liver Disease</i> , 2013, 45, 840-843.	0.9	47
62	Virological and Clinical Response to Interferon-Free Regimens in Patients with HCV-Related Mixed Cryoglobulinemia: Preliminary Results of a Prospective Pilot Study. <i>Current Drug Targets</i> , 2017, 18, 772-785.	2.1	47
63	Interferon-alpha in mixed cryoglobulinemia patients: a randomized, crossover-controlled trial. <i>Blood</i> , 1993, 81, 1132-6.	1.4	46
64	Non-Hodgkin's Lymphoma: Possible Role of Hepatitis C Virus. <i>JAMA - Journal of the American Medical Association</i> , 1994, 272, 355.	7.4	44
65	â€œInapparentâ€ hepatitis B virus infection and hepatitis C virus replication in alcoholic subjects with and without liver disease. <i>Hepatology</i> , 1994, 19, 577-582.	7.3	44
66	Impaired response to alpha interferon in patients with an inapparent hepatitis B and hepatitis C virus coinfection. <i>Archives of Virology</i> , 1997, 142, 535-544.	2.1	43
67	The hepatitis C virus infection as a systemic disease. <i>Internal and Emergency Medicine</i> , 2012, 7, 201-208.	2.0	42
68	Role of MicroRNA Profile Modifications in Hepatitis C Virus-Related Mixed Cryoglobulinemia. <i>PLoS ONE</i> , 2013, 8, e62965.	2.5	42
69	Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study. <i>PLoS ONE</i> , 2017, 12, e0172159.	2.5	42
70	Retreatment regimen of rituximab monotherapy given at the relapse of severe HCV-related cryoglobulinemic vasculitis: Long-term follow up data of a randomized controlled multicentre study. <i>Journal of Autoimmunity</i> , 2015, 63, 88-93.	6.5	41
71	Exacerbation of peripheral neuropathy during alpha-interferon therapy in a patient with mixed cryoglobulinemia and hepatitis B virus infection. <i>Journal of Rheumatology</i> , 1996, 23, 1641-3.	2.0	38
72	Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network. <i>PLoS ONE</i> , 2017, 12, e0185728.	2.5	37

#	ARTICLE	IF	CITATIONS
73	Thyroid cancer in HCV-related mixed cryoglobulinemia patients. <i>Clinical and Experimental Rheumatology</i> , 2002, 20, 693-6.	0.8	37
74	Polymyositis, lung fibrosis, and cranial neuropathy in a patient with hepatitis C virus infection. <i>Arthritis and Rheumatism</i> , 1996, 39, 1074-1075.	6.7	36
75	Association between mixed cryoglobulinemia, translocation (14;18), and persistence of occult HCV lymphoid infection after treatment. <i>Hepatology</i> , 2006, 43, 1166-1167.	7.3	35
76	Hepatitis C virus infection and B-cell lymphomas. <i>European Journal of Cancer</i> , 1994, 30, 1591-1592.	2.8	34
77	Free light chains: Eclectic multipurpose biomarker. <i>Journal of Immunological Methods</i> , 2017, 451, 11-19.	1.4	33
78	Forecasting Hepatitis C liver disease burden on real-life data. Does the <i>hidden iceberg</i> matter to reach the elimination goals?. <i>Liver International</i> , 2018, 38, 2190-2198.	3.9	33
79	HBV and HCV chronic infection: Autoimmune manifestations and lymphoproliferation. <i>Autoimmunity Reviews</i> , 2008, 8, 107-111.	5.8	32
80	Efficacy and safety of peginterferon alfa-2b plus ribavirin for HCV-positive mixed cryoglobulinemia: a multicentre open-label study. <i>Clinical and Experimental Rheumatology</i> , 2011, 29, 933-41.	0.8	32
81	Effect of alpha-interferon on hepatitis C virus chronic infection in mixed cryoglobulinemia patients. <i>Infection</i> , 1993, 21, 93-97.	4.7	31
82	Association of t(14;18) translocation with HCV infection in gastrointestinal MALT lymphomas. <i>Journal of Hepatology</i> , 2008, 49, 170-174.	3.7	31
83	Transient elastography for the assessment of liver fibrosis in patients with chronic viral hepatitis: The missing tool?. <i>Digestive and Liver Disease</i> , 2009, 41, 863-866.	0.9	31
84	Long-lasting persistence of large B-cell clones in hepatitis C virus-cured patients with complete response of mixed cryoglobulinaemia vasculitis. <i>Liver International</i> , 2019, 39, 628-632.	3.9	31
85	Chronic hepatitis C and B-cell non-Hodgkin's lymphoma. <i>QJM - Monthly Journal of the Association of Physicians</i> , 1996, 89, 117-122.	0.5	30
86	HCV patients, psychopathology and tryptophan metabolism: analysis of the effects of pegylated interferon plus ribavirin treatment. <i>Digestive and Liver Disease</i> , 2007, 39, S107-S111.	0.9	30
87	Combined Treatment with Antiviral Therapy and Rituximab in Patients with Mixed Cryoglobulinemia: Review of the Literature and Report of a Case Using Direct Antiviral Agents-Based Antihepatitis C Virus Therapy. <i>Case Reports in Immunology</i> , 2015, 2015, 1-5.	0.4	28
88	Interferon-free therapy in hepatitis C virus mixed cryoglobulinaemia: a prospective, controlled, clinical and quality of life analysis. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 440-450.	3.7	28
89	Elevated serum levels of osteopontin in HCV-associated lymphoproliferative disorders. <i>Cancer Biology and Therapy</i> , 2005, 4, 1192-1194.	3.4	27
90	HCV-related cryoglobulinemic vasculitis: an update on its etiopathogenesis and therapeutic strategies. <i>Clinical and Experimental Rheumatology</i> , 2003, 21, S78-84.	0.8	26

#	ARTICLE	IF	CITATIONS
91	Can BAFF promoter polymorphism be a predisposing condition for HCV-related mixed cryoglobulinemia?. <i>Blood</i> , 2008, 112, 4353-4354.	1.4	25
92	Modeling cost-effectiveness and health gains of a universal versus prioritized hepatitis C virus treatment policy in a real-life cohort. <i>Hepatology</i> , 2017, 66, 1814-1825.	7.3	25
93	Performance of the preliminary classification criteria for cryoglobulinaemic vasculitis and clinical manifestations in hepatitis C virus-unrelated cryoglobulinaemic vasculitis. <i>Clinical and Experimental Rheumatology</i> , 2012, 30, S48-52.	0.8	25
94	Association between persistent lymphatic infection by hepatitis C virus after antiviral treatment and mixed cryoglobulinemia. <i>Blood</i> , 2008, 111, 2943-2945.	1.4	24
95	Non-invasive assessment of liver fibrosis in patients with HBV-related chronic liver disease undergoing antiviral treatment: A preliminary study. <i>European Journal of Pharmacology</i> , 2017, 806, 105-109.	3.5	24
96	Direct medical costs associated with the extrahepatic manifestations of hepatitis C infection in Europe. <i>Journal of Viral Hepatitis</i> , 2018, 25, 811-817.	2.0	24
97	Frequency of bcl-2 rearrangement in patients with mixed cryoglobulinemia and HCV-positive liver diseases. <i>Clinical and Experimental Rheumatology</i> , 1997, 15, 711-2.	0.8	22
98	Correspondence. <i>British Journal of Haematology</i> , 1997, 98, 778-782.	2.5	20
99	Hepatitis C virus-related mixed cryoglobulinemia: Is genetics to blame?. <i>World Journal of Gastroenterology</i> , 2013, 19, 8910.	3.3	20
100	Role of the HLA Class II: HCV-Related Disorders. <i>Annals of the New York Academy of Sciences</i> , 2007, 1107, 308-318.	3.8	19
101	Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel. <i>Digestive and Liver Disease</i> , 2017, 49, 731-741.	0.9	19
102	Hepatitis B Virus-Related Cryoglobulinemic Vasculitis: Review of the Literature and Long-Term Follow-Up Analysis of 18 Patients Treated with Nucleos(t)ide Analogues from the Italian Study Group of Cryoglobulinemia (GISC). <i>Viruses</i> , 2021, 13, 1032.	3.3	19
103	Hepatitis C Virus, B-Cell Disorders, and Non-Hodgkin's Lymphoma. , 0, , 349-368.		19
104	Improvement in liver cirrhosis after treatment of HCV-related mixed cryoglobulinemia with rituximab. <i>Digestive and Liver Disease</i> , 2007, 39, S129-S133.	0.9	18
105	Hepatitis C virus core protein expression in human B-cell lines does not significantly modify main proliferative and apoptosis pathways. <i>Journal of General Virology</i> , 2002, 83, 1665-1671.	2.9	18
106	Treatment of HCV-Related Mixed Cryoglobulinemia. <i>Current Drug Targets</i> , 2017, 18, 794-802.	2.1	18
107	Involvement of PI3K in HCV-related lymphoproliferative disorders. <i>Journal of Cellular Physiology</i> , 2008, 214, 396-404.	4.1	17
108	Assessment of free light chains in HCV-positive patients with mixed cryoglobulinaemia vasculitis undergoing rituximab treatment. <i>Liver International</i> , 2015, 35, 2100-2107.	3.9	17

#	ARTICLE	IF	CITATIONS
109	IgG3 subclass: A possible trigger of mixed cryoglobulin cascade in hepatitis C virus chronic infection. <i>Digestive and Liver Disease</i> , 2017, 49, 1233-1239.	0.9	17
110	Value of IL28B genotyping in patients with HCV-related mixed cryoglobulinemia: results of a large, prospective study. <i>Journal of Viral Hepatitis</i> , 2013, 20, e107-14.	2.0	16
111	Impact of Immunogenetic IL28B Polymorphism on Natural Outcome of HCV Infection. <i>BioMed Research International</i> , 2014, 2014, 1-8.	1.9	16
112	HCV-related liver and lymphoproliferative diseases: association with polymorphisms of IL28B and TLR2. <i>Oncotarget</i> , 2016, 7, 37487-37497.	1.8	16
113	Analysis of interleukin (IL)-1beta IL-1 receptor antagonist, soluble IL-1 receptor type II and IL-1 accessory protein in HCV-associated lymphoproliferative disorders. <i>Oncology Reports</i> , 2006, 15, 1305-8.	2.6	16
114	Hepatitis-C virus infection and cancer. <i>Journal of Hepatology</i> , 1997, 26, 1113-1115.		15
115	Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 427-434.	8.1	15
116	Lymphotropic Virus Infection of Peripheral Blood Mononuclear Cells in B-Cell Non-Hodgkin's Lymphoma. <i>Acta Haematologica</i> , 1997, 98, 89-94.	1.4	14
117	Hepatitis C virus core protein enhances B lymphocyte proliferation. <i>Digestive and Liver Disease</i> , 2007, 39, S72-S75.	0.9	14
118	The liver-cytokine-brain circuit in interferon-based treatment of patients with chronic viral hepatitis. <i>Journal of Viral Hepatitis</i> , 2011, 18, 525-532.	2.0	14
119	Hepatitis C virus infection in the immunocompromised host: a complex scenario with variable clinical impact. <i>Journal of Translational Medicine</i> , 2012, 10, 158.	4.4	14
120	Assessment of liver stiffness in patients with HCV and mixed cryoglobulinemia undergoing rituximab treatment. <i>Journal of Translational Medicine</i> , 2014, 12, 21.	4.4	14
121	MicroRNA expression in hepatitis C virus-related malignancies: A brief review. <i>World Journal of Gastroenterology</i> , 2015, 21, 8562.	3.3	14
122	Autoimmunity and lymphoproliferation markers in naive HCV-RNA positive patients without clinical evidences of autoimmune/lymphoproliferative disorders. <i>Digestive and Liver Disease</i> , 2016, 48, 927-933.	0.9	14
123	Parallel increase of circulating CXCL11 and CXCL10 in mixed cryoglobulinemia, while the proinflammatory cytokine IL-6 is associated with high serum Th2 chemokine CCL2. <i>Clinical Rheumatology</i> , 2013, 32, 1147-1154.	2.2	13
124	From current status to optimization of HCV treatment: Recommendations from an expert panel. <i>Digestive and Liver Disease</i> , 2016, 48, 995-1005.	0.9	13
125	Longitudinal evaluation of liver stiffness and outcomes in patients with chronic hepatitis C before and after short- and long-term IFN-free antiviral treatment. <i>Current Medical Research and Opinion</i> , 2020, 36, 245-249.	1.9	13
126	Enhanced TH1 cytokine production in hepatitis C virus-infected patients with mixed cryoglobulinemia: understanding the pathological issues. <i>Journal of Hepatology</i> , 2004, 41, 1045-1049.	3.7	12

#	ARTICLE	IF	CITATIONS
127	Covid-19 And Rheumatic Autoimmune Systemic Diseases: Role of Pre-Existing Lung Involvement and Ongoing Treatments. <i>Current Pharmaceutical Design</i> , 2021, 27, 4245-4252.	1.9	12
128	Evaluation of the prognostic value of liver stiffness in patients with hepatitis C virus treated with triple or dual antiviral therapy: A prospective pilot study. <i>World Journal of Gastroenterology</i> , 2015, 21, 3013.	3.3	12
129	Flares of mixed cryoglobulinaemia vasculitis after vaccination against SARS-CoV-2. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 441-443.	0.9	12
130	A prospective study of direct-acting antiviral effectiveness and relapse risk in HCV cryoglobulinemic vasculitis by the Italian PITER cohort. <i>Hepatology</i> , 2022, 76, 220-232.	7.3	12
131	A stereotyped light chain may shape virus-specific B-cell receptors in HCV-dependent lymphoproliferative disorders. <i>Genes and Immunity</i> , 2020, 21, 131-135.	4.1	11
132	Notch4 and mhc class II polymorphisms are associated with hcv-related benign and malignant lymphoproliferative diseases. <i>Oncotarget</i> , 2017, 8, 71528-71535.	1.8	11
133	Hepatitis C virus in mixed cryoglobulinemia and B cell lymphoma. <i>Clinical and Experimental Rheumatology</i> , 1994, 12, 89-90.	0.8	11
134	Effect of chronic hepatitis C virus infection on inflammatory lipid mediators. <i>Digestive and Liver Disease</i> , 2007, 39, S76-S82.	0.9	10
135	Reply. <i>Hepatology</i> , 2017, 65, 1771-1772.	7.3	10
136	Different biochemical patterns in type II and type III mixed cryoglobulinemia in HCV positive patients. <i>Digestive and Liver Disease</i> , 2018, 50, 938-943.	0.9	10
137	Expert Opinion on Managing Chronic HCV in Patients with Mixed Cryoglobulinaemia Vasculitis. <i>Antiviral Therapy</i> , 2018, 23, 1-9.	1.0	10
138	Hematological and Genetic Markers in the Rational Approach to Patients With HCV Sustained Virological Response With or Without Persisting Cryoglobulinemic Vasculitis. <i>Hepatology</i> , 2021, 74, 1164-1173.	7.3	10
139	Predictors of long-term cryoglobulinemic vasculitis outcomes after HCV eradication with direct-acting antivirals in the real-life. <i>Autoimmunity Reviews</i> , 2022, 21, 102923.	5.8	10
140	Modifications of plasma platelet-activating factor (PAF)-acetylhydrolase/PAF system activity in patients with chronic hepatitis C virus infection. <i>Journal of Viral Hepatitis</i> , 2007, 14, 22-28.	2.0	9
141	Effect of FCGR polymorphism on the occurrence of late-onset neutropenia and flare-free survival in rheumatic patients treated with rituximab. <i>Arthritis Research and Therapy</i> , 2017, 19, 44.	3.5	9
142	Sentinel biomarkers in HCV positive patients with mixed cryoglobulinemia. <i>Journal of Immunological Methods</i> , 2020, 476, 112687.	1.4	9
143	Sofosbuvir/Velpatasvir for the treatment of Hepatitis C Virus infection. <i>Acta Biomedica</i> , 2018, 89, 321-331.	0.3	9
144	Role of Notch Receptors in Hematologic Malignancies. <i>Cells</i> , 2021, 10, 16.	4.1	9

#	ARTICLE	IF	CITATIONS
145	Monoclonal gammopathy in patients with chronic hepatitis C virus infection. <i>Blood</i> , 1996, 88, 1122.	1.4	9
146	Etiopathogenetic role of hepatitis C virus in mixed cryoglobulinemia, chronic liver diseases and lymphomas. <i>Clinical and Experimental Rheumatology</i> , 1995, 13 Suppl 13, S135-40.	0.8	9
147	Hepatitis C-associated B-cell non-Hodgkin lymphomas: The emerging role of miRNA-26b. <i>Journal of Hepatology</i> , 2013, 59, 1362-1363.	3.7	8
148	A randomized, controlled study of peginterferon lambda-1a/ribavirin±Aadaclatasvir for hepatitis C virus genotype 2 or 3. <i>SpringerPlus</i> , 2016, 5, 1365.	1.2	8
149	Antiviral therapy in hepatitis C-infected patients prevents relapse of diffuse large B cell lymphoma. <i>Clinical and Experimental Hepatology</i> , 2018, 4, 197-200.	1.3	8
150	Real life experiences in HCV management in 2018. <i>Expert Review of Anti-Infective Therapy</i> , 2019, 17, 117-128.	4.4	8
151	Safety and effectiveness of biosimilar of Rituximab CT-P10 in the treatment of cryoglobulinemic vasculitis: the MARBLE study (Mixed cryoglobulinemia Rituximab BiosimiLar). <i>Internal and Emergency Medicine</i> , 2021, 16, 149-156.	2.0	8
152	HCV-Related Rheumatic Manifestations and Therapeutic Strategies. <i>Current Drug Targets</i> , 2017, 18, 803-810.	2.1	8
153	Direct-Acting Antivirals as Primary Treatment for Hepatitis C Virus-Associated Indolent Non-Hodgkin Lymphomas: The BART Study of the Fondazione Italiana Linfomi. <i>Journal of Clinical Oncology</i> , 2022, 40, 4060-4070.	1.6	8
154	JH6 Gene Usage among HCV-Associated MALT Lymphomas Harboring t(14;18) Translocation. <i>Journal of Immunology</i> , 2005, 174, 3839.1-3839.	0.8	7
155	Deregulation of microRNA expression in peripheral blood mononuclear cells from patients with HCV-related malignancies. <i>Hepatology International</i> , 2015, 9, 586-593.	4.2	7
156	Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis. <i>Infection</i> , 2018, 46, 607-615.	4.7	7
157	Latent hepatitis B virus (HBV) infection in systemic necrotizing vasculitis. <i>Clinical and Experimental Rheumatology</i> , 1991, 9, 23-8.	0.8	7
158	Prevalence and Death Rate of COVID-19 in Autoimmune Systemic Diseases in the First Three Pandemic Waves. Relationship with Disease Subgroups and Ongoing Therapies. <i>Current Pharmaceutical Design</i> , 2022, 28, 2022-2028.	1.9	7
159	Hepatitis C Virus and Mixed Cryoglobulinaemia. <i>Rheumatology</i> , 1994, 33, 301-301.	1.9	6
160	High Circulating Chemokines (C-X-C Motif) Ligand 9, and (C-X-C Motif) Ligand 11, in Hepatitis C-Associated Cryoglobulinemia. <i>International Journal of Immunopathology and Pharmacology</i> , 2013, 26, 49-57.	2.1	6
161	Effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients: Results of the Italian cohort of a post-marketing observational study. <i>Digestive and Liver Disease</i> , 2021, 53, 612-619.	0.9	6
162	Hepatitis C virus as a lymphotropic agent: evidence and pathogenetic implications. <i>Clinical and Experimental Rheumatology</i> , 1995, 13 Suppl 13, S33-7.	0.8	6

#	ARTICLE	IF	CITATIONS
163	Reducing the price of new hepatitis C drugs in the Tuscany region of Italy. <i>BMJ</i> , The, 2015, 350, h3363-h3363.	6.0	5
164	Mixed cryoglobulinaemia: An important but frequently unrecognized and underestimated <sc>HCV</sc>-related condition in the real life practice. <i>Liver International</i> , 2018, 38, 183-183.	3.9	5
165	Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN). <i>Digestive and Liver Disease</i> . 2018. 50. 1133-1152.	0.9	5
166	The Relevance of MicroRNAs in the Pathogenesis and Prognosis of HCV-Disease: The Emergent Role of miR-17-92 in Cryoglobulinemic Vasculitis. <i>Viruses</i> , 2020, 12, 1364.	3.3	5
167	Current and future challenges in HCV: insights from an Italian experts panel. <i>Infection</i> , 2018, 46, 147-163.	4.7	4
168	Solving the mystery of HBV-related mixed cryoglobulinemia: potential biomarkers of disease progression. <i>Rheumatology</i> , 2021, 60, 4418-4427.	1.9	4
169	Impact of direct acting antivirals on hepatitis C virus-related cryoglobulinemic syndrome. <i>Minerva Gastroenterology</i> , 2021, 67, 218-226.	0.5	4
170	Rapid improvement of psychiatric stigmata after IFN-free treatment in HCV patients with and without cryoglobulinemic vasculitis. <i>Clinical Rheumatology</i> , 2022, 41, 147-157.	2.2	4
171	Bâ€cell activating factor (BAFF), BAFF promoter and BAFF receptor allelic variants in hepatitis C virus related Cryoglobulinemic Vasculitis and Nonâ€Hodgkin's Lymphoma. <i>Hematological Oncology</i> , 2022, , .	1.7	4
172	HCV infection, malignancy, and liver transplantation. <i>Transplantation Proceedings</i> , 2003, 35, 1032-1033.	0.6	3
173	The Expanding Spectrum of Clinical Features in HCV-Related Mixed Cryoglobulinemia. , 2012, , 155-162.		3
174	Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN). <i>Journal of Nephrology</i> , 2018, 31, 685-712.	2.0	3
175	Epidemiological, demographic and clinical data on chronic viral hepatitis C in Tuscany. <i>Current Medical Research and Opinion</i> , 2019, 35, 661-666.	1.9	3
176	<i>PDCD1</i> and <i>IFNL4</i> genetic variants and risk of developing hepatitis C virusâ€related diseases. <i>Liver International</i> , 2021, 41, 133-149.	3.9	3
177	Treatment or Prophylaxis against Hepatitis B Virus Infection in Patients with Rheumatic Disease Undergoing Immunosuppressive Therapy: An Update. <i>Journal of Clinical Medicine</i> , 2021, 10, 2564.	2.4	3
178	Lack of preferential localization of tumoral mass in B-cell non-Hodgkin's lymphoma associated with hepatitis C virus infection. <i>Blood</i> , 1997, 89, 3066-8.	1.4	3
179	SARS-CoV-2 was already circulating in Italy, in early December 2019. <i>European Review for Medical and Pharmacological Sciences</i> , 2021, 25, 3342-3349.	0.7	3
180	Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN). <i>Internal and Emergency Medicine</i> , 2018, 13, 1139-1166.	2.0	2

#	ARTICLE	IF	CITATIONS
181	REPLY: Hepatology, 2021, 74, 2910-2910.	7.3	1
182	Direct antiviral agents for treatment-naïve patients with genotype 1 hepatitis C: A statistical model for comparing outcomes between real world and clinical trials. Digestive and Liver Disease, 2015, 47, 988-989.	0.9	0
183	Editorial: interferon-free DAAs are a great boon for patients with hepatitis C and cryoglobulinaemia—Authors' reply. Alimentary Pharmacology and Therapeutics, 2018, 48, 772-773.	3.7	0
184	Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN). Infection, 2019, 47, 141-168.	4.7	0
185	Hepatitis C Virus Lymphotropism and Possible Pathogenetic Implications.. , 1996, , 251-259.		0
186	Fibrosis Assessment in Patients with HCV or HBV Chronic Infection. , 2020, , 113-121.		0
187	Reply. Hepatology, 2022, 76, E11-E12.	7.3	0